Immunization with components of two iron uptake ABC transporters protects mice against systemic Streptococcus pneumoniae infection

被引:137
作者
Brown, JS
Ogunniyi, AD
Woodrow, MC
Holden, DW
Paton, JC
机构
[1] Univ London Imperial Coll Sci Technol & Med, Sch Med, Ctr Mol Microbiol & Infect, London SW7 2AZ, England
[2] Univ Adelaide, Dept Mol Biosci, Adelaide, SA 5005, Australia
关键词
D O I
10.1128/IAI.69.11.6702-6706.2001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
There has been considerable recent research into protein based Streptococcus pneumoniae vaccines as alternatives to the existing capsular antigen vaccines. PiuA and PiaA (formerly Pit1A and Pit2A) are recently identified lipoprotein components of S. pneumoniae iron uptake ABC transporters which are required for full virulence and are likely to be expressed on the surface of the bacterial cell membrane. We investigated the efficacy of recombinant PiuA and PiaA proteins at eliciting protective immunity in mice against systemic infection with S. pneumoniae. Both recombinant PiuA and PiaA generated antibody responses that crossreacted with each other but not with pneumolysin and reacted with identical proteins from nine different S. pneumoniae serotypes. Mice immunized with recombinant PiuA and PiaA were protected against systemic challenge to a degree similar to those immunized with an existing protein vaccine candidate, PdB (a genetically modified pneumolysin toxoid). Immunization with a combination of both PiuA and PiaA resulted in additive protection and was highly protective against systemic infection with S. pneumoniae. PiuA and PiaA are therefore promising additional candidates for a novel S. pneumoniae vaccine using protein antigens.
引用
收藏
页码:6702 / 6706
页数:5
相关论文
共 25 条
  • [1] IMMUNIZATION OF MICE WITH PNEUMOLYSIN TOROID CONFERS A SIGNIFICANT DEGREE OF PROTECTION AGAINST AT LEAST 9 SEROTYPES OF STREPTOCOCCUS-PNEUMONIAE
    ALEXANDER, JE
    LOCK, RA
    PEETERS, CCAM
    POOLMAN, JT
    ANDREW, PW
    MITCHELL, TJ
    HANSMAN, D
    PATON, JC
    [J]. INFECTION AND IMMUNITY, 1994, 62 (12) : 5683 - 5688
  • [2] STREPTOCOCCUS-PNEUMONIAE - VIRULENCE FACTORS, PATHOGENESIS, AND VACCINES
    ALONSODEVELASCO, E
    VERHEUL, AFM
    VERHOEF, J
    SNIPPE, H
    [J]. MICROBIOLOGICAL REVIEWS, 1995, 59 (04) : 591 - &
  • [3] STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC ACID FRACTION ISOLATED FROM PNEUMOCOCCUS TYPE III
    Avery, Oswald T.
    MacLeod, Colin M.
    McCarty, Maclyn
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1944, 79 (02) : 137 - 158
  • [4] Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
    Black, S
    Shinefield, H
    Fireman, B
    Lewis, E
    Ray, P
    Hansen, JR
    Elvin, L
    Ensor, KM
    Hackell, J
    Siber, G
    Malinoski, F
    Madore, D
    Chang, I
    Kohberger, R
    Watson, W
    Austrian, R
    Edwards, K
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) : 187 - 195
  • [5] Systemic and mucosal protective immunity to pneumococcal surface protein A
    Briles, DE
    Tart, RC
    Wu, HY
    Ralph, BA
    Russell, MW
    McDaniel, LS
    [J]. MICROBIAL PATHOGENESIS AND IMMUNE RESPONSE II, 1996, 797 : 118 - 126
  • [6] A Streptococcus pneumoniae pathogenicity island encoding an ABC transporter involved in iron uptake and virulence
    Brown, JS
    Gilliland, SM
    Holden, DW
    [J]. MOLECULAR MICROBIOLOGY, 2001, 40 (03) : 572 - 585
  • [7] ANTIBODY-RESPONSE TO PNEUMOCOCCAL VACCINATION IN CHILDREN YOUNGER THAN 5-YEARS OF AGE
    DOUGLAS, RM
    PATON, JC
    DUNCAN, SJ
    HANSMAN, DJ
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1983, 148 (01) : 131 - 137
  • [8] Efficacy of a pneumococcal conjugate vaccine against acute otitis media
    Eskola, J
    Kilpi, T
    Palmu, A
    Jokinen, J
    Haapakoski, J
    Herva, E
    Takala, A
    Käyhty, H
    Karma, P
    Kohberger, R
    Siber, G
    Mäkela, PH
    Lockhart, S
    Ecrola, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (06) : 403 - 409
  • [9] Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I
    Hausdorff, WP
    Bryant, J
    Paradiso, PR
    Siber, GR
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 30 (01) : 100 - 121
  • [10] 1ST AND 2ND DOSE ANTIBODY-RESPONSES TO PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN INFANTS
    KOSKELA, M
    LEINONEN, M
    HAIVA, VM
    TIMONEN, M
    MAKELA, PH
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1986, 5 (01) : 45 - 50